Formula's Italian CAR

Formula enters CAR T cell race with non-viral technology

Formula Pharmaceuticals Inc. has licensed a chimeric antigen receptor (CAR) technology from Fondazione Matilde Tettamanti Menotti De Marchi Onlus that it thinks will be safer and more efficient than other CAR T cell approaches because it uses non-viral transfection and is based on allogeneic cytokine-induced killer cells that lower

Read the full 494 word article

How to gain access

Continue reading with a
two-week free trial.